etravirine has been researched along with grazoprevir in 2 studies
| Studies (etravirine) | Trials (etravirine) | Recent Studies (post-2010) (etravirine) | Studies (grazoprevir) | Trials (grazoprevir) | Recent Studies (post-2010) (grazoprevir) |
|---|---|---|---|---|---|
| 572 | 90 | 321 | 160 | 42 | 153 |
| Protein | Taxonomy | etravirine (IC50) | grazoprevir (IC50) |
|---|---|---|---|
| Genome polyprotein | 0.0007 | ||
| Non-structural protein 4A | 0.0007 | ||
| NS3 protease | Hepatitis C virus subtype 1b | 0.0044 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Converso, A; Daublain, P; El Marrouni, A; Kesisoglou, F; Lipert, MP; Templeton, AC; Wuelfing, WP | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
2 other study(ies) available for etravirine and grazoprevir
| Article | Year |
|---|---|
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery.
Topics: Administration, Oral; Animals; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Discovery; Humans; Oral Mucosal Absorption; Pharmaceutical Preparations; Solubility | 2022 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |